scPharmaceuticals, Inc. Target price 2024 - Analyst rating & recommendation
scPharmaceuticals, Inc. Classifications & Recommendation:
scPharmaceuticals, Inc. Target price
| Target price | $19.50 |
| Course | $4.35 |
| Price potential |
348.28%
register free of charge
|
| Number of estimates | 6 |
|
6 Analysts have issued a price target scPharmaceuticals, Inc. 2025 .
The average scPharmaceuticals, Inc. target price is $19.50.
This is
348.28%
register free of charge
$25.00
474.71%
register free of charge
$16.00
267.82%
register free of charge
|
|
| A rating was issued by 6 analysts: 5 Analysts recommend scPharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst estimates: Analysts believe that the scPharmaceuticals, Inc. share has an average upside potential 2025 of
348.28%
register free of charge
|
Sales and margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Turnover Million $ | 13.59 | 39.33 |
| 189.43% | ||
| EBITDA margin | -403.02% | -140.64% |
| 65.10% | ||
| Net margin | -376.68% | -133.12% |
| 64.66% |
6 Analysts have issued a sales forecast scPharmaceuticals, Inc. 2024 . The average scPharmaceuticals, Inc. sales estimate is
This results in the following potential growth figures:
1 Analyst has issued an EBITDA forecast scPharmaceuticals, Inc. 2024 . The average scPharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth figures and future EBITDA margins:
4 scPharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average scPharmaceuticals, Inc. net profit estimate is
This results in the following potential growth figures and future net margins:
Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Earnings per share $ | -1.42 | -1.45 |
| 9.23% | 2.11% | |
| P/E ratio | negative | |
| EV/Sales | 3.54 |
4 Analysts have issued a scPharmaceuticals, Inc. forecast for earnings per share. The average scPharmaceuticals, Inc. <a href=/blog/eps>EPS is
This results in the following potential growth figures and future valuations:
Based on analysts' sales estimates for 2024, the scPharmaceuticals, Inc. share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth figures and future valuations:
scPharmaceuticals, Inc....
Discover more stocks with a high price target
Register for free
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.
